(Reuters) - The long-awaited ruling provides much needed certainty for one of the world's largest selling products, and immediately revived debate on Wall Street about a Bristol-Myers takeover.
"The decision will help solidify Bristol-Myers' earnings and dividend, and perhaps open the door for another drugmaker -- most logically Sanofi -- to come in at this point and purchase Bristol," Jason Fox, an analyst at H&R Block Financial Advisors.
Read more at Reuters.com Business News
"The decision will help solidify Bristol-Myers' earnings and dividend, and perhaps open the door for another drugmaker -- most logically Sanofi -- to come in at this point and purchase Bristol," Jason Fox, an analyst at H&R Block Financial Advisors.
Read more at Reuters.com Business News
No comments:
Post a Comment